Although 90-95% of adults recover completely from Hepatitis B (HBV) infection, a minority are unable to clear the virus 1 . Epidemiological studies have demonstrated an increased risk of B-NHL among those with persistent HBV and B-NHL [2] [3] [4] [5] . Yet the roles of exposure per se, occult infection, antibody response and viral clearance remain unclear.
Occult HBV infection (OBI) signifies persistence of the viral genome in blood and liver tissue, in patients without hepatitis B surface antigen (HBsAg), with or without antibodies to hepatitis B core (anti-HBc) or hepatitis B surface (anti-HBs). Most subjects with OBI are in fact positive for anti-HBc and negative for HBsAg, while some are seronegative for all HBV markers 6 . The association between OBI and B-NHL is clinically important due to the risk of reactivation of HBV following immunotherapy or chemotherapy; however, few studies have addressed OBI as a risk factor for NHL [7] [8] [9] .
Immune response to HBV (defined as anti-HBs) is elicited either by natural response to viral exposure (anti-HBc+ with anti-HBs+) or by vaccination (anti-HBc-with anti-HBs+). Limited data have suggested a negative association between the presence of anti-HBs and B-NHL 7, 8 .
Heredity plays a role in NHL etiology, as evidenced by the doubling of risk in first-degree relatives of NHL patients 10 . It is unknown whether host genetic factors related to viral clearance are also related to NHL susceptibility.
The role of HBV infection in B-NHL has not been previously evaluated in Israel or the West Bank, where HBsAg seroprevalence has been estimated at 0.22 to 1.8% respectively 11, 12 . In a case-control study (Supplemental Methods) we explored associations between exposure, persistence, and immune response to HBV with overall B-NHL as well as with two major subtypes: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), in these populations. Additionally, we assessed whether a family history of hematopoietic malignancies was associated with HBV persistence.
We recruited 823 (516-Israelis/307-Palestinians) incident cases of B-NHL (median time from diagnosis-three months). DLBCL was the most common histology, comprising 427 (52%)
cases while FL was diagnosed in 186 (23%). We recruited 808 healthy controls (414-Israelis/394-Palestinians) from among individuals accompanying patients to hospital or health centers. Cases and controls (Supplemental Table 1 ) differed in distributions of sex, age, marital status and family history of hematopoietic malignancies (P<0.01 for all); thus we adjusted for these variables in our models.
HBV serology was performed in 96.8% of participants (see results of individual markers, Table 1a ). Most seromarkers (with the exception of eAg), including anti-HBc, HBsAg, anti-
HBs and e-antibodies (anti-HBe) were more prevalent among Palestinians than Israelis. In contrast, antibody response to vaccine was more prevalent among Israelis. In addition, the combination of anti-HBc+ without anti-HBs, representing lack of immune response to HBV, was more common in Palestinians (9.0% vs. 3.0% in Israelis, P<0.0001) (Table 1b) . Casecontrol association patterns were similar in the two groups.
Comparing cases and controls we found that persistence of HBV, as evidenced by HBsAg+ was associated with DLBCL (odds ratio (OR)=2.39, 95% confidence-interval (CI):1. 5 , respectively. In the latter study, investigators did not detect HBV-DNA in lymphoma tissues, but found HBV S, X, and C genes in DNA extracted from peripheral blood mononuclear cells, suggesting an indirect effect on lymphomagenesis 5 .
In the current study, the presence of anti-HBc was not associated with B-NHL or its subtypes, implying that exposure to HBV per se is not a risk factor for B-NHL. This finding is supported by a single Japanese cohort study of 20,360 subjects 13 .
Chen et al 9 
Authorship Contributions
GK -Performed and coordinated the Israeli population study, responsible for data collection, data analysis, statistical modeling, data interpretation, literature search, figures, and writing of the manuscript.
RAS -Performed and coordinated the Palestinian population study, responsible for data collection, lab work, data interpretation, writing of the manuscript.
RP -Participated in training of study personnel, study design, obtaining funding, data collection and interpretation.
ZA -Designed and supervised the Palestinian side of the project, facilitated access to patients and controls, data collection, data interpretation, writing of the manuscript.
AK -Served as PI at one study site (AVH), supervised viral serology performance, participated in data interpretation, writing of the manuscript.
HE -Was responsible for data collection at Beit Jalla Hospital, data interpretation.
ED -Providing patients and manuscript revision.
MK -Providing patients and manuscript revision.
ME -Providing patients and manuscript revision.
AN -Was the PI in one site (Sheba Tel Hashomer), responsible for data collection at the site, writing of the manuscript.
GA -Provided pathology expertise, data interpretation, writing of the manuscript.
DBY -Involved in study design, facilitated patient recruitment, aided in obtaining IRB approval and funding, data interpretation, writing of the manuscript.
RS -Provided hepatology expertise, interpretation of serologic data, writing of the manuscript.
OP -Was responsible for the study design, obtaining IRB approval and funding, data collection, review of clinical data, interpretation of data and writing of the manuscript.
All authors reviewed and approved the final manuscript.
Disclosure of Conflicts of Interest
There is no conflict of interest with any of the authors of this manuscript. 
Tables

Supplemental Methods
Study design
This is a hospital and community-based case-control study in Israel and the West Bank including Palestinians and Israelis (Supplemental Methods). For purposes of analysis Israeli citizens of Muslim origin were grouped together with Palestinians.
Study population
Inclusion criteria
We enrolled incident cases (target: within 18 months of diagnosis), aged ≥18 years, with pathologically confirmed CD20+ (or other B-cell marker+) B-NHL, and healthy controls aged ≥18
years accompanying or visiting out-and inpatients 1 in participating centers.
Exclusion criteria were inability to provide written informed consent; HIV positivity; being a blood relative of a case; and being a spouse of an enrolled case for Palestinian controls (given frequent cousin marriages).
Recruitment:
Cases 
Study variables
Participants were interviewed in Hebrew, Arabic, Russian or English utilizing a questionnaire adapted from that used in the European Epilymph study 2 . Questionnaire items included demographic characteristics as well as family and medical history (reported separately).
Hepatitis B Biomarkers
Serum samples were obtained and tested for the presence of HBsAg, anti-HBc, anti-HBs, hepatitis B e antibodies (anti-HBe) and hepatitis B e antigen (HBeAg), by ELISA (Roche Elecsys, Basel, Switzerland) at AVH.
Anti-HBc+ individuals were considered "exposed" to HBV. Among these, individuals who were
HBsAg+ were considered to have persistent infection while those HBsAg-were considered to have occult infection (OBI). Individuals who demonstrated anti-HBs+ with anti-HBc-were considered immune via vaccine, while anti-HBs+ with anti-HBc+ were considered naturally immune via exposure, although some of the individuals designated "vaccinated" might actually be naturally immune. Individuals who were anti-HBc+ and anti-HBs-were considered to lack immune response following viral exposure.
Statistical analysis
Distribution of baseline variables in cases and controls were assessed using two-sided Fisher's exact 
Role of the funding source
The funding sources played no role in the design, execution or analysis of the study.
Supplemental Table 1 Supplemental B-NHL=B-cell non-Hodgkin lymphoma; DLBCL= diffuse large B-cell lymphoma; FL=follicular lymphoma; P * calculated for overall B-NHL versus controls; Values were missing for < 5% for exposure variable; † Education was not significantly associated with case control status but highly associated with HBV exposure, hence it was included in multivariable models.
